期刊
MOVEMENT DISORDERS
卷 32, 期 4, 页码 510-525出版社
WILEY
DOI: 10.1002/mds.26968
关键词
Parkinson's disease; atypical parkinsonism; MRI; iron; neuromelanin; diffusion MRI; fMRI; resting state fMRI; 7T
资金
- Agence Nationale de la Recherche (ANRMNP)
- Direction de l'hospitalisation et de l'offre de soins (DHOS)-Inserm
- France Parkinson
- Ecole Neuroscience de Paris
- Investissements d'avenir [ANR-10-IAIHU-06, ANR-11-INBS-0006]
- National Institutes of Health [R01 NS052318, R01 NS075012]
- Medical University Innsbruck
- Oesterreichische Nationalbank Nationalbank (Austrian Central Bank, Anniversary Fund) [14174]
- Austrian Science Fund (Fonds zur Wissenschaftlichen Forschung (FWF): Der Wissenschaftsfonds) [KLI82-B00]
- Canadian Institutes for Health Research [MOP-81114]
- Canada Research Chair in nonmotor symptoms of Parkinson's disease
- Tourmaline Oil Chair in Parkinson's disease
- Neureca Foundation
- Horizon [643706]
- Italian National Research Project [RF-2009-1530177]
- AbbVie
- Angelini
- Acadia
- UCB
- Zambon
- General Electric
- Boston Scientific
- Medtronic
- Mundipharma
- Global Kinetics
- Mottershead Foundation
- National Parkinson's Foundation
- Parkinson's Society of Canada
- University of British Columbia / Pacific Parkinson's Research Institute (UBC/PPRI) chair in Parkinson's Research
- Teva
- Roche
- Axovant
- Novartis
- Canadian Institutes of Health Research
- Ministry of Economic Development and Innovation Research
- Innovation and Science (Ontario)
- Weston Brain Institute
- Sunny-brook AFP Innovation Fund
- Washington University
- Parkinson Society Canada
- Alzheimer's Drug Discovery Foundation
- Brain Canada
- Ontario Brain Institute
- Michael J. Fox Foundation
- Janssen Pharmaceutica N.V.
- German Parkinson's Disease Association (dPV)
- Bundesministerium fur Wirtschaft und Energie (BMWi)
- Forderung in der Forschung (BBF)
- Parkinson Fonds Deutschland gGmbH
- UCB Pharma GmbH
- TEVA Pharma GmbH
- Europe (EU)
- Novartis Pharma GmbH
- Lundbeck
- Wellcome Trust - Astra Zeneca Medimmune [103838]
- Allergan
- Lundbeck Foundation [R59-2010-5399, R186-2015-2138] Funding Source: researchfish
- Medical Research Council [MR/M009041/1, MR/M008983/1, MC_U105597119, MC_UU_00005/12] Funding Source: researchfish
- Wellcome Trust [103838/Z/14/Z] Funding Source: researchfish
- MRC [MR/M024873/1, MR/M009041/1, MC_U105597119, MR/M008983/1, MC_UU_00005/12] Funding Source: UKRI
Historically, magnetic resonance imaging (MRI) has contributed little to the study of Parkinson's disease (PD), but modern MRI approaches have unveiled several complementary markers that are useful for research and clinical applications. Iron- and neuromelanin-sensitive MRI detect qualitative changes in the substantia nigra. Quantitative MRI markers can be derived from diffusion weighted and iron-sensitive imaging or volumetry. Functional brain alterations at rest or during task performance have been captured with functional and arterial spin labeling perfusion MRI. These markers are useful for the diagnosis of PD and atypical parkinsonism, to track disease progression from the premotor stages of these diseases and to better understand the neurobiological basis of clinical deficits. A current research goal using MRI is to generate time-dependent models of the evolution of PD biomarkers that can help understand neurodegeneration and provide reliable markers for therapeutic trials. This article reviews recent advances in MRI biomarker research at high-field (3T) and ultra high field-imaging (7T) in PD and atypical parkinsonism. (c) 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据